Research programme: transdermal NSAIDs - SK Drug Development CenterAlternative Names: YKPPN
Latest Information Update: 10 Jul 2009
At a glance
- Originator SK Bio-Pharmaceuticals
- Developer SK Drug Development Center
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 01 Jan 2009 Discontinued - Preclinical for Pain in South Korea (unspecified route)
- 17 Aug 2005 Preclinical trials in Pain in South Korea (unspecified route)